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Summary 
In addition to their well characterized high af~nity immunoglobulin E (IgE) receptors (FceRl) 
mast cells have long been suspected to express undefined Fc receptors capable of binding IgE 
with low a6inity. In this paper, we show that Fc~RII and Fc3'RIII, but not Mac-2, on mouse 
mast cells and macrophages bind IgE-immune complexes. This binding is ef~ciently competed 
by 2.4G2, a monoclonal antibody against the extraceUular homologous region of both Fc3'RII 
and Fc3'RIII.  Furthermore,  IgE-immune complexes bind  specifically  to  Fc~tLII or Fc~RIII 
transfected into COS-7 cells. The association constants of IgE binding estimated from competition 
experiments are about 3.1  x  10  s M -t for Fc~RII, and 4.8  x  10  s M -1 for Fc3,RIII.  Engagement 
of Fc3`RII  and Fc~RIII with IgE-immune complexes (after blocking access to FceRI) or with 
IgG-immune complexes triggers C57.1 mouse mast cells to release serotonin. This release is inhibited 
by 2.4G2, and at maximum, reaches 30-40% of the intracellular content, about half of the maximal 
release (60-80%) obtained after FceRI engagement. These data demonstrate that mouse Fc~RII 
and Fc~RIII are not isotype specific, and that the binding of IgE-immune complexes to these 
receptors induces cell activation. 
T 
he molecular cloning of IgE-receptors has helped to clas- 
sify these receptors into two very different families of 
proteins. The high affinity IgE receptor (FceRI)* is a non- 
covalent tetrameric complex of an ~x chain, a 13 chain, and 
two disulfide-linked 3' chains (1, 2). The high affinity binding 
site of FceRI is on the oz chain, a structure homologous to 
other Fc receptors and a member of the Ig superfamily. By con- 
trast, low af~nity IgE-binding structures are part of the lectin- 
like receptor family. One of these, FceRII or CD23, belongs 
to the calcium-dependent class of animal lectins (3, 4) and 
the other, Mac-2, also called CBP35  and eBP (5,  6), is of 
the thiol-dependent class of animal lectins. 
The tissue distribution and function of these receptors are 
also very different. The high affinity IgE receptor is found 
on the surface of mast cells, basophils (1), and Langerhans 
cells (7).  Crosslinking of this receptor via IgE and antigen 
results in release of the mediators that cause the symptoms 
1  Abbreviations used in this paper: F(ab')z, antigen binding fragment of 
immunoglobulin molecule obtained by pepsin digestion; Fc, constant 
fragment  of immunoglobulin  molecule;  FcylLII,  low affinity  receptor  for 
IgG; Fc'yRlI1,  low affinity  receptor  for IgG; FceRI, high affinity  receptor 
for IgE; and FceRII, low affinity  receptor for IgE. 
of allergic diseases. CD23 in humans is expressed on a wide 
variety of hemopoietic cells, among them B and T cells, but 
in mice, the expression of CD23 appears  to be restricted to 
B cells (3). The role of CD23 is not yet completely under- 
stood, but it has been proposed to regulate IgE synthesis, 
to endocytose IgE-immune complexes in B cells, and to serve 
as an adhesion molecule. Mac-2 was originally described as 
a macrophage cell surface marker (8), but it is also expressed 
in mast cells and fibroblasts (5,  6).  In spite of the lack of 
a typical transmembrane domain, a proportion of Mac-2 mol- 
ecules in these cells are attached to the cell surface. The mech- 
anism of membrane anchoring may involve binding to cell 
surface glycoconjugates, because incubation of cells with lac- 
tose disrupts the attachment (9). In solution, Mac-2 binds 
IgE, but this binding is carbohydrate dependent and has not 
been demonstrated for surface-expressed molecules, so its phys- 
iological relevance is at best speculative. 
More than a decade ago, two molecules with different mo- 
lecular weight were isolated by affinity chromatography on 
IgE-Sepharose from extracts of rat basophilic leukemia cells 
and rat mast cells (10, 11). Then rat basophilic leukemia cells 
were shown to express IgG receptors also capable of binding 
IgE (12).  In fact, these receptors seemed to have a greater 
a~nity for rat IgE than for rat IgG (12,  13). Other reports 
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rat lymphocytes (14) or to rat macrophages (15).  However, 
this inhibition was characterized as unidirectional and was 
thought  to be unique for rat cells  (16). 
Our original goal was  to characterize the putative low 
affinity IgE/IgG receptor on rodent mast cells by molecular 
methods. Despite the restriction of earlier studies to the rat 
system, we decided to use mouse mast cells because antibodies 
are available  against the various structures known to bind 
IgE or IgG. We found that the two low affinity receptors 
for IgG (Fc3'RII/III) known to be expressed on the surface 
of mouse mast cells (17,  18) and macrophages (19), are also 
low affinity receptors for IgE. 
Materials  and Methods 
Iraraunoglobulins.  Igs  were  purchased  from  the  following 
sources: rabbit IgG and goat anti-rabbit  IgG F(ab')2-FITC from 
Organon Teknika (West Chester, PA); mouse monoclonal anti- 
Dansyl IgE from Pharmingen  (San Diego, CA); mouse anti-rat 
IgG (Fc-specific)  from Jackson Immunoresearch Laboratories  (West 
Grove, PA); and mouse monoclonal IgG2b from Southern Biotech- 
nology Associates (Birmingham,  AL).  The FITC-labded  anti- 
mouse FceRII antibody B3B4 (20) was a gift of Dr. D. H. Conrad 
(Medical College of Virginia, Richmond, VA). The anti-rat Mac-2 
antiserum, which crossreacts with the mouse protein, was a gift 
of Dr. F.-T. Liu (Scripps Clinic, La  Jolla, CA). Mouse monoclonal 
anti-DNP IgE (H1 DNP-e-26.82) (21) was purified from ascites 
as previously  described (22) or it was purified by ion exchange chro- 
matography on DEAE-Trisacryl  (IBF Biotechnics, Columbia, MD) 
from culture supernatant of the hybridoma grown in Protein-Free 
Hybridoma Medium (Gibeo BRL, Grand Island, NY) in a Mini 
Flo-Path bioreactor (Amicon, Beverly,  MA). Mouse anti-DNP IgE 
was labded with FITC by standard procedures (23). Rabbit anti- 
mouse IgE (22) and mouse anti-DNP IgG (24) were prepared as 
described. The rat mAb 2.4G2 (anti-mouse Fc3`RII and -Ill) (25) 
was purified from tissue culture supernatant by Protein-G affinity 
chromatography (Pharmacia LKB Biotechnology, Piscataway, NJ). 
To make oligomers, 100 mg/ml rabbit IgG or mouse monoclonal 
IgE were chemically  crosslinked using dimethyl suberimidate (Pierce 
Chemical Co., Rockford,  IL) (12) at a crosslinker/protein molar 
ratio of 10:1 at 30~  for 3 h. Rabbit IgG dimers were obtained 
from this preparation by size separation on Sephacryl S-300 HR 
(Pharmacia LKB Biotechnology). They were radioiodinated using 
chloramine T as described (23). To prepare immune complexes, 1 
mg/ml anti-DNP IgG or anti-DNP IgE were incubated with DNP- 
albumin (Calbiochem  Corp., LaJolh, CA) at molar ratios of 1:1-20:1 
at 4~  for 1 h and used without further washing. Monomeric IgG 
and IgE were separated from aggregates by centrifuging at 130,000 
g for 45 min in an Airfuge (Beckman Instruments, Inc., Fullerton, 
CA).  Only the upper 3/4 of the samples were used. 
Cells.  COS-7, J774A.1,  P388D1, and P815 (American Type 
Culture Collection, Rockville, MD) were grown in DMEM with 
2 mM glutamine, 10% FCS, 100 U/ml penicillin, and 100/zg/ml 
streptomycin (Biofluids Inc.,  Rockville, MD) at 37~  in a hu- 
midified atmosphere containing  5% CO2. The mouse mast call 
line C1.MC/C57.1  (C57.1) (26), a gift of S. J. Galli (Beth Israel 
Hospital, Boston, MA), was maintained in DMEM as were the 
other cell lines, except for the further addition of 5 #M 13-ME. 
Expression Vectors.  cDNAs encoding mouse Fc3`RII and the c~ 
chain of Fc3`RIII (19) were gifts ofJ. V. Ravetch (Memorial Sloan- 
Kettering Cancer Center, New York). The cDNA for the 3, subunit 
common to mouse FceRI and F~RIII was previously described 
(27). The expression vector pCDbSRot296 (28) was a gift of N. 
Arai (DNAX Research Institute of  Molecular and Cellular Biology, 
Palo Alto, CA). The cDNAs encoding mouse Fc3,RII and -III were 
ligated into the XbaI and SacI sites of pCDbSR~296, the cDNA 
encoding the 3' subunit was ligated into the EcoRI and Sad sites. 
Transfection.  Transfections  were  carried  out  by the DEAE- 
Dextran method (29) using 5  x  106 COS-7 cells per 162 cm  2 flask 
and 10 #g of each cDNA-containing vector. The amount of DNA 
was adjusted to a total of 30 #g by adding carrier DNA. After 
48 h, the cells were harvested with Enzyme Free Cell Dissociation 
Solution (Specialty Media, Lavallette, NJ). For negative controls, 
the 3` subunit  was transfected alone. 
Flow Cytoraetric Analysis.  Flow cytometric analyses were per- 
formed on a FACScan  |  (Becton Dickinson & Co., Palo Alto, CA). 
For binding  of monomeric  IgE or IgE-immune  complexes, 10  s 
cells were incubated with 10/~g/ml  of monomeric IgE-FITC or 
immune complexes  oflgE-FITC and DNP-albumin at 4~  for 2 h 
and then washed twice with PBS containing 0.1% BSA and 0.1% 
NAN3. For removal of cell surface Mac-2, the same buffer was used 
with the further addition of 25 mM lactose (8). For binding  of 
oligomeric IgG, the cells were incubated with 10/~g/ml of rabbit 
IgG oligomer at 4~  for 2 h and washed. Goat anti-rabbit IgG 
F(ab')2-FITC was  used  as  the  second antibody  to  detect  IgG 
binding to the cells. Unstained cells or the cells stained with the 
second antibody alone were used as negative controls. For compet- 
itive inhibition, cells  were preincubated  with 50/~g/ml 2.4(32 and/or 
50 #g/ml unlabeled IgE at 4~  for 2 h before addition of oligo- 
meric IgG or labeled IgE. 
Competition Binding Experiments.  Competitive binding of t2sI- 
labeled rabbit IgG dimers and unlabeled monomeric Igs to trans- 
fected cells was studied as previously described (12). Briefly, cells 
transfected with either Fc3`RII or -III or the 3` subunit alone were 
incubated with 10/~g/ml radiolabeled rabbit  IgG dimer (corre- 
sponding to 6.7  x  10 -s M IgG molecules) and varying concen- 
trations of  unlabeled monomeric mouse monoclonal IgG2b, rabbit 
IgG, or mouse monoclonal anti-DNP IgE (molar ratios of mono- 
mer/dimer 0.6:1-150:1, based on IgG molecules). The cell density 
was 2  x  107/ml, the buffer was PBS containing 0.2% BSA, and 
the incubation was at 4~  for 2 h. Cells were centrifuged through 
phthalate oil (6 volume parts dibutyl phthalate,  4 volume parts 
bis(ethylhexyl)phthalate) to separate bound from unbound ligand. 
Percent cell-bound radioactivity was calculated by dividing cpm 
in the cell pellet by total cpm. Nonspedfic binding was determined 
with transfectants expressing 3` alone and subtracted from the per- 
cent binding value to give percent specific  binding. The degree of 
inhibition by various monomeric Igs was calculated by setting the 
specific binding in the absence of inhibitors equal to 0% inhibi- 
tion.  100% inhibition was defined as absence of specific binding 
as a consequence of inhibition. Saturation binding assays with in- 
creasing amounts of radiolabeled IgG dimers were performed be- 
fore the competition binding experiments to verify expression of 
the receptors and to determine optimal conditions. 
Serotonin Release.  C57.1  cells were cultured with 1/~Ci/ml of 
5-[1,2-3H(N)]-hydroxytryptamine  binoxalate  ([~H]-serotonin) 
(DuPont Co.,  Wilmington, DE) for 16 h.  All procedures after 
labeling were performed in buffer containing  25 mM Na2Pipes 
(pH 7.1), 100 mM NaCI,  5 mM KC1, 0.4 mM MgC12, 1 mM 
CaC12, 5.6 mM D-glucose, and 0.1% BSA (30). Cells were satu- 
rated with monomeric IgE, 2.4G2, or both at 37~  for 1 h and 
washed. The cells were challenged by rabbit anti-mouse IgE or 
multivalent antigen (DNP-albumin) for triggering through FceRI. 
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linked with anti-rat IgG (Fc-specific). When IgE and/or 2.4G2 
were used as inhibitors, these inhibitors were resupplemented after 
saturation and washing, and the cells were challenged by IgG- or 
IgE-immune complexes. The reaction was stopped after 30 min 
by placing the tubes on ice and sedimenting the cells for 3 min 
at  4,000  rpm  in  a  microfuge.  Radioactivity  was  determined 
separately in the pellet and the supernatant.  Percent release was 
calculated  by dividing counts per minute in the supematant by total 
counts/min. 
Results and Discussion 
Cell Surface Receptors on C57.1.  Our first goal was to es- 
tablish unequivocally whether IgE binds to a second site on 
mast cells other than FceKI. This, and the identification of 
the binding site, requires antibodies against cell surface pro- 
reins known to bind IgG or IgE. For murine ceils,  several 
useful antibodies are available,  such as 2.4G2, which binds 
to the extraceilular domains of the highly homologous Fc'/KII 
and -III receptors and blocks the binding of IgG (25), or B3B4, 
which recognizes mouse FceRII (20). Comparable anti-rat 
reagents are not known. Therefore, we analyzed the mouse 
mast call line C57.1 rather than the rat cell line RBL, which 
had been studied previously. We first characterized relevant 
ceil  surface proteins  on  this  cell line  (Table  1).  C57.1  is 
FceKI + , FceKII-, F~KII/III + , and Mac-2 + . Mac-2 can be 
removed from the cell surface by lactose, as has been described 
for RBL (9). The cell line responds to engagement of FceKI 
in the same way as R.BL  (30a). 
2.4G2-inhibitable Binding of lgE-immune Complexes to Mast 
Cells.  To investigate binding of Igs to their surface, C57.1 
ceils were incubated with monomeric antibody or with im- 
mune complexes and analyzed by flow cytometry. Monomeric 
IgE strongly binds to C57.1 (Fig. 1 A). This binding is com- 
pletely inhibited by excess  unlabeled monomeric IgE  (50 
#g/ml) (Fig. 1 B). There is no further inhibition when both 
excess IgE and 2.4G2 are employed (Fig. 1 C). This is consis- 
tent with the presence of a single dass of high affinity binding 
sites for IgE on these ceils, i.e., FceKI receptors. IgE-immune 
complexes also strongly bind to C57.1  (Fig.  1 D).  In con- 
trast to the binding of monomeric IgE, the binding of im- 
Table  1.  Cell Su~'ace Recepton for lgE and lgG 
on  (?,57.1 Mast  Cells 
Surface antigen  Antibody  Staining 
FceKI  IgE (Monomeric)  + + + 
FceKII  B3B4  - 
Fc'yKII/III  2.4G2  + + 
Mac-2  Antiserum  + 
Cells were stained with the antibodies shown above, and analyzed by 
flow cytometry. Anti-Mac-2 staining could be abolished  by incubation 
of C57.1 with 25 mM lactose in flow cytometry buffer. 
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mune complexes is not completely inhibited by excess mono- 
meric IgE (Fig. 1 E), indicating that IgE-immune complexes 
do indeed bind to a second site in addition to FceKI. How- 
ever, the binding of immune complexes is completely blocked 
by the combination of excess monomeric IgE and FcyKII/III- 
specific 2.4G2 (Fig. 1 F). This demonstrates that the staining 
not inhibited by monomeric IgE is due to a cell surface struc- 
ture recognized by 2.4G2. Further binding, which could be 
attributed to other structures such as Mac-2, is not detected. 
These experiments were performed with monodonal anti- 
DNP IgE purified from serum-flee bioreactor supernatant 
to ensure there is no contamination with other Ig dasses and 
repeated with a preparation of the same antibody from as- 
cites.  No difference between the two preparations was de- 
tected. Oligomerized IgG binds to C57.1  (Fig.  1 G).  It is 
not surprising that its binding is inhibited by 2.4G2  (Fig. 
1 H), and also by IgE-immune complexes (Fig.  1/). Thus, 
on C57.1, IgE and IgG bind to the same low affinity binding 
site,  which reacts  with  2.4G2  and  is  therefore likely an 
Fc'yKII/III receptor. These findings confirm those of Segal 
et al. (12), who described mutually inhibitable low affinity 
binding of IgE and IgG to the RBL mast cell line, and ex- 
tend them by pointing towards Fc~/RII/III as the respon- 
sible entity. 
Binding of lgE-immune Complexes to Macrophage Cell Lines 
and  to  a Fc6RI-deficient Mast  Cell  Line.  We  investigated 
whether this low affinity, 2.4G2-reactive binding site was 
also present on ceil types that express Fc'yKII/III receptors 
but not FceRI. J774, a mouse monocyte-macrophage  cell line 
(31), does not bind monomeric IgE (Fig. 2 A), but does bind 
IgE-immune complexes to a site that is blocked by 2.4G2 
(Fig. 2 B). In the same way, 2.4G2 blocks binding of oligo- 
meric IgG (Fig.  2 C). J774  stains  with an anti-rat Mac-2 
antiserum, which crossreacts with the mouse protein. The 
staining is abolished by prior incubation of the cells with 
25 mM lactose, indicating that Mac-2 binds to cell surface 
conjugates on J774.  However, the binding of IgE-immune 
complexes to J774 is not affected by this treatment (data not 
shown). Together with the lack of a third binding site for 
IgE on C57.1, this observation excludes Mac-2 from the ranks 
of functional cell surface IgE receptors. The ability of cell 
surface Mac-2 to bind IgE has also been questioned on theo- 
retical grounds (9), because the protein, which does not have 
a transmembrane region, apparently attaches to the cell sur- 
face by binding a membrane glycoconjugate and cannot bind 
IgE simultaneously. Essentially the same results were obtained 
with P388D1 (macrophage-like) (32), and the mastocytoma- 
like P815 (33) (data not shown), which express Fc3,KII and 
-III but not FcdLI (18, 34). This is further evidence that the 
low affinity binding site for IgE on mast cells and macro- 
phages is an Fc'yKII/III receptor. 
Binding of IgE-immune Complexes to ~ansfected Low A~nity 
Fc~ Receptors.  So far, the identification of the low affinity 
binding site for IgE as FcTKII/III rests entirely on its reac- 
tivity with 2.4G2. However, if there exists an IgE/IgG receptor 
unrelated to Fc'yKII/III which either crossreacts with 2.4G2 
or binds this antibody via its Fc part, it would simulate the 
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Figure 1.  Binding of monomeric IgE, IgE- 
immune complexes,  and  oligomeric  IgG  to 
C57.1 mast cells. Cells  were incubated with 
FITC-conjugated  monomeric lgE (A-C),  or 
with FITC-conjugated IgE-immune complexes 
(D--F),  or  with  IgG  oligomer  followed  by 
FITC-conjugated goat anti-rabbit IgG F(ab')z 
(C-/).  The binding was either not inhibited 
(buffer control: A, D, and G) or inhibited with 
unlabeled monomeric IgE (/3 and E), or with 
monomeric  IgE  and  2.4G2  (C  and  F),  or 
with 2.4G2 alone (H), or with unlabeled IgE- 
immune complexes  (/). Background  staining 
(dotted lines) was assessed using no antibody or 
only the secondary antibody. 
circumvented with F(ab')2 fragments of 2.4G2, but even low 
levels of contaminating whole antibody molecules can inter- 
fere (35). Furthermore, the question of crossreactivity is not 
addressed by this approach. Therefore,  we decided  to posi- 
tively identify the receptors by transiently  transfecting  the 
genes for the single chain of mouse FcyRII and the two chains 
(c~ and "y) required for surface expression of mouse FcyRIII 
(34) into COS-7 cells. Control cells which were transfected 
with the y  subunit alone bound neither oligomeric IgG nor 
IgE-immune complexes (Fig. 3 E and F). Cells which tran- 
siently expressed Fc'yRII bound IgE-immune complexes (Fig. 
3 B),  as well as oligomeric IgG (Fig.  3 A).  In both cases 
the binding was completely inhibited by 2.4G2.  A  similar 
staining was observed with cells expressing Fcq~RIII (Fig. 3, 
C and D). This result shows that the so-called IgG receptors 
FcyRII and -III are not isotype specific; they bind IgE and 
are thus functional Fce receptors. 
A~nity of  FryRII and Fc'yRIII  for IgE.  Because  the binding 
of monomeric antibody to Fcq~RII/III is too weak to mea- 
sure, our experiments have relied on the increased avidity of 
oligomers and complexes of antibodies  to visualize binding 
to the Fc3' receptors. The avidity of such a complex depends 
on its size,  therefore it cannot be used in measurements  of 
affinity constants.  In this situation, the relative affinities of 
different antibodies can be determined by allowing the mono- 
meric antibody to compete with rabbit IgG dimers, whose 
binding is  sufficiently  strong to be measurable. 
COS-7 cells,  which transiently  expressed either  Fc34~II 
or FcyRIII,  were incubated  with radiolabeled IgG dimers 
and either monomeric mouse IgG2b, rabbit IgG, or mouse 
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Figure  2.  Binding  of lgE-immune complexes  and oligomeric lgG to 
J774 macrophages. J774 were incubated with monomeric FITC-labeled 
IgE (A) FITC-labeled IgE-immune complexes (B), or rabbit IgG oligomers 
followed by FITC-conjugated  goat anti-rabbit  IgG F(ab')2. The binding 
was not inhibited (buffer control: solid lines) or inhibited with 2.4G2 (dashed 
lines). Background  staining (dotted lines) was assessed using no antibody 
or only the secondary antibody. 
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Figure 3.  Binding of lgE-immune complexes  and IgG oligomers to 
COS-7 transfectants.  COS-7 were transfected with the genes for FcTR.II 
(.4 and B), the cx and ~/subunits of FeTKIII (C and D), or the "7 subunit 
alone (E and F). Cells were incubated with rabbit IgG oligomers followed 
by FITC-conjugated goat anti-rabbit IgG F(ab')2 (.4, C, and E) or with 
FITC-conjugated IgE-immune complexes (B, D, and F). The binding was 
either not inhibited (buffer control: solid lines) or inhibited with 2.4G2 
(dashed lines). Background staining (dotted lines) was assessed using no an- 
tibody or only the secondary  antibody. 
Table  2,  Serotonin  Release from  C57.1  Mast  Cells through 
Fc'yRII/III  or FceRI 
Percent  serotonin 
Preincubation  Challenge  release 
(-)  (-)  0.9  _+  0.2 
2.4G2  (-)  1.0  _+  0.1 
(-)  Anti-rat IgG  1.2  _+  0.1 
2.4G2  Anti-rat IgG  33.2  _+  0.2 
(-)  Mouse  IgG immune  25.2  _+  1.0 
complex 
2.4G2  Mouse  IgG immune  1.3  +_  0.4 
complex 
Anti-Dansyl IgE  (-)  2.9  +_  0.5 
(+)  Anti-mouse  IgE  1.1  _+  0.2 
Anti-Dansyl IgE  Anti-mouse  IgE  62.6  +_  1.3 
Cells were preincubated with buffer alone, or with 2.4G2 (25/~g/ml), 
or with monomeric mouse anti-Dansyl IgE (25 ~g/ml) and washed, and 
then challenged by either mouse anti-DNP IgG immune complexes (5 
/~g/ml IgG), or anti-rat IgG (5 /zg/ml), or rabbit anti-mouse IgE (5 
#g/ml).  Values  are means  •  SD of triplicate determinations. 
IgE.  The molar ratio  of monomers/dimers (based on IgG 
molecules) varied between 0.6 and 150. IgE was less efficient 
than either rabbit IgG or mouse IgG2b at competing with 
dimers for binding to Fc'yKII (Fig. 4, left), and as efficient 
as rabbit IgG, but less so than mouse IgG2b, at competing 
for FcyKIII (Fig. 4, right).  The approximate association con- 
stants for the different monomeric Ig classes are calculated 
from the reciprocals of the concentration required for half- 
maximal inhibition of dimer binding.  From the inhibition  r  3  [  ! 
|  Fcy R II  |  |  Fcy R III  [  values  obtained, we estimate the association constant between 
100  100  FcyRII and mouse IgG2b, rabbit IgG, and mouse IgE as 7.7 
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Figure 4.  Displacement of IgG dimers from F~RII and FeTRIII by  2  4  s  e  10  0  ~0  20  3o  4o  50 
IgG and IgE. COS-7 were transfected either with Fc3,RII (/eft) or FcTIlI 
(or and 31 subunits, right). They were incubated with lzSI-labeled rabbit 
IgG dimers (10/~g/ml, corresponding to 6.7  x  10 -s M IgG molecules) 
and increasing amounts of monomeric mouse IgG2b (e), monomeric rabbit 
IgG (O) or monomeric mouse IgE (I). Inhibitors and labeled IgG dimers 
were premixed before the addition of cells. The degree of inhibition was 
calculated by setting percent specific binding of IgG dhuers without in- 
hibitors equal to 0% inhibition. 100% inhibition was defined as absence 
of specific binding as a result of competition. Values are means •  SEM. 
Error bars are omitted where they fall within the size of the data symbol 
IgE CONCENTRATION (/~g/ml) 
Figure 5.  Serotonin release from C57.1  mast cells triggered by IgE- 
immune  complexes  or chemically crosslinked  IgE.  Cells loaded with 
[3H]serotonin  were triggered by IgE-immune complexes (/eft) or chemi- 
cally crosslinked IgE (right). Triggering was either not inhibited (O), or 
inhibited by 2.4G2 alone (I), monomeric IgE alone (e), or monomeric 
IgE and 2.4G2  (D). Values are means  _+  SD calculated from triplicate 
samples. Error bars are omitted where they fall within the size of the data 
symbol. 
473  Takizawa et al. x  10  sM -1,9.1  x  10  sM -rand3.1  x  10  sM -t,respec- 
tively, and for the binding to Fc'yRIII, 6.7  x  106 M -t, 3.6 
x  10  s M -1, and 4.8  x  105 M -t. The order of magnitude 
of these figures agrees well with published values for the in- 
teraction between Fc3,RII/III and IgG (36-38),  and with 
values for the interaction between IgE and the low affinity 
receptor on mast cells (12), although in these earlier studies 
differentiation between the subclasses of Fc'y receptors was 
not possible. 
We disagree with Segal et al. (12) on the relative affinities 
of IgG and IgE for the low affinity receptor. They estimated 
the affinity of IgE for the low affinity receptor on mast cells 
to be almost four times as high as that of rabbit IgG, whereas 
according to our experiments, IgG has the higher affinity. 
Here it is important to remember that Segal et al. (12) used 
mast cells for their experiments. Incomplete blocking of FceRI 
may account for the difference. 
Activation of Mast Cells by IgE through Fc'yRII/III.  To dem- 
onstrate that host defences, especially activation of mast cells, 
can be mediated by IgE through Fc'y receptors, we investigated 
Fc'ytLII/III-mediated serotonin release from C57.1 cells. First, 
we established that C57.1 can be activated through Fc3,RII 
and -III. This can be shown with IgG-immune complexes 
(Table 2; 25.2% release, inhibited to 1.3 % by prior blocking 
with 2.4G2) or by crosslinking receptor-bound 2.4G2 with 
a secondary anti-rat antibody (33.2%  release).  There is no 
response to 2.4G2 alone (1.0% release), presumably because 
it is an insufficient stimulus to crosslink Fc3~RII/III to mere 
dimers. Even with optimized crosslinking, the response to 
Fc'yR stimulation is much weaker than that to FceRI stimu- 
lation (62.6% release after crosslinking of FceRI-bound IgE). 
We do not know whether this reflects merely a difference 
in receptor number or a difference in the signaling mechanism. 
We then investigated whether stimulation through F~ILII/ 
III contributes to activation when C57.1 cells are triggered 
by immune complexes of monodonal anti-DNP IgE and DNP- 
albumin (Fig.  5, left) or by chemically crosslinked IgE (Fig. 
5, right). With both of these triggering agents a comparable 
plateau of serotonin release ('~70%) is reached. 2.4G2 alone 
does not  inhibit release.  However, if binding of the IgE- 
immune complexes to  FceRI is  selectively inhibited with 
monomeric IgE, serotonin release is reduced to about one 
half of the release observed without inhibition. There is an 
even greater inhibition when both FceRI and Fc3,RII/III are 
blocked. The magnitude of this further inhibition corresponds 
well with that of IgG-mediated release through Fc'yRII/III. 
IgE can thus  trigger mast cells  through both FceRI and 
FcyRII/III. 
To summarize, we have unequivocally shown that: mouse 
IgE binds with low affinity to a site on mast cells other than 
FcetLI; that this site corresponds to the mouse IgG receptor 
Fc3~RII/III also found on cell types such as macrophages; 
that the affinity of IgE for the receptors is comparable with 
that of IgG; and that the binding is functional, because it 
contributes to mast cell activation. Our goal is now to inves- 
tigate whether these findings are also relevant to the human 
system. In that case, our findings would have dramatic im- 
plications for explaining the role of IgE in parasitic diseases 
(39).  It might be argued that in view of the serum levels 
of IgE, binding of IgE to Fc3,RII or Fc~/RIII will not occur 
under physiological conditions, and in any case will be com- 
peted by much higher levels of IgG. However, the affinity 
of these receptors is comparably low for IgG. In fact, normal 
macrophages are capable of binding IgG-immune complexes 
because most of the receptors are empty in physiological con- 
ditions.  It is therefore probable that IgE- as well as IgG- 
immune complexes will bind to these receptors and activate 
relevant defence systems, particularly in situ, where the con- 
centration of immune complexes relative to monomeric ligand 
might be much higher than in the serum. 
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